AdvaMed Tells US FDA Which Guidelines Need To Be Finalized First
This article was originally published in SRA
US medtech trade group AdvaMed is calling on the Food and Drug Administration to prioritize completing five of the 12 final guidelines that the agency has said it intends to finalize in fiscal year 2016, including guidelines on medical device accessories and unique device identification (UDI) direct marking1,2.
You may also be interested in...
Drug companies in the EU explain how a new pilot scheme on national-level scientific advice service can benefit drug developers.
While the Dutch government negotiates an acceptable price for Leadiant Biosciences’ orphan drug CDCA, a university hospital has resumed supplying pharmacy compounded versions of the drug after addressing initial problems with the sourcing of raw materials.
The European Court of Justice has confirmed the European Medicines Agency’s approach to disclosure of data submitted as part of a marketing authorization application. It is a big disappointment for industry, which nonetheless says it supports responsible data sharing and will support efforts to develop a balanced approach.